Planning for cell and gene therapy trials requires an understanding of the product, control of unique supply chains, access to ultra cold-chain technologies, and global reach combined with local knowledge.
Come join Edward Groleau, PCI’s Director of Clinical Supply Chain for North America and our guest speaker Scott Ohanesian, QuickSTAT’s Sr. VP of Commercial Operations and Clinical Trial Logistics as they discuss cell & gene therapy supply strategies, including:
- Packaging and labeling requirements for cell and gene therapy material
- Distribution considerations including track and trace
- Ultra cold chain technologies
- Supply chain control for autologous vs. allogeneic therapies